Titre : Endotoxines

Endotoxines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostate
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Endotoxines : Questions médicales les plus fréquentes", "headline": "Endotoxines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Endotoxines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-12", "dateModified": "2025-02-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Endotoxines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Toxines bactériennes", "url": "https://questionsmedicales.fr/mesh/D001427", "about": { "@type": "MedicalCondition", "name": "Toxines bactériennes", "code": { "@type": "MedicalCode", "code": "D001427", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Lipopolysaccharides", "alternateName": "Lipopolysaccharides", "url": "https://questionsmedicales.fr/mesh/D008070", "about": { "@type": "MedicalCondition", "name": "Lipopolysaccharides", "code": { "@type": "MedicalCode", "code": "D008070", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123.329.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Lipide A", "alternateName": "Lipid A", "url": "https://questionsmedicales.fr/mesh/D008050", "about": { "@type": "MedicalCondition", "name": "Lipide A", "code": { "@type": "MedicalCode", "code": "D008050", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123.329.500.500" } } }, { "@type": "MedicalWebPage", "name": "Antigènes O", "alternateName": "O Antigens", "url": "https://questionsmedicales.fr/mesh/D019081", "about": { "@type": "MedicalCondition", "name": "Antigènes O", "code": { "@type": "MedicalCode", "code": "D019081", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123.329.500.600" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Endotoxines", "alternateName": "Endotoxins", "code": { "@type": "MedicalCode", "code": "D004731", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Johannes Reich", "url": "https://questionsmedicales.fr/author/Johannes%20Reich", "affiliation": { "@type": "Organization", "name": "Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Stanberger See, Germany. j.reich@microcoat.de." } }, { "@type": "Person", "name": "Guy C Brown", "url": "https://questionsmedicales.fr/author/Guy%20C%20Brown", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK. gcb3@cam.ac.uk." } }, { "@type": "Person", "name": "John A Kellum", "url": "https://questionsmedicales.fr/author/John%20A%20Kellum", "affiliation": { "@type": "Organization", "name": "Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA." } }, { "@type": "Person", "name": "Gary Hannon", "url": "https://questionsmedicales.fr/author/Gary%20Hannon", "affiliation": { "@type": "Organization", "name": "Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland." } }, { "@type": "Person", "name": "Adriele Prina-Mello", "url": "https://questionsmedicales.fr/author/Adriele%20Prina-Mello", "affiliation": { "@type": "Organization", "name": "Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36651430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/acb371205" } }, { "@type": "ScholarlyArticle", "name": "Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review.", "datePublished": "2022-07-13", "url": "https://questionsmedicales.fr/article/35696302", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/bju.15823" } }, { "@type": "ScholarlyArticle", "name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.", "datePublished": "2023-05-26", "url": "https://questionsmedicales.fr/article/37271051", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmpb.2023.107624" } }, { "@type": "ScholarlyArticle", "name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36917412", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11255-023-03531-2" } }, { "@type": "ScholarlyArticle", "name": "Prostatic artery embolization compared to transurethral resection of the prostate and prostatic urethral lift: a real-world population-based study.", "datePublished": "2022-12-04", "url": "https://questionsmedicales.fr/article/36463348", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00345-022-04218-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Toxines biologiques", "item": "https://questionsmedicales.fr/mesh/D014118" }, { "@type": "ListItem", "position": 4, "name": "Toxines bactériennes", "item": "https://questionsmedicales.fr/mesh/D001427" }, { "@type": "ListItem", "position": 5, "name": "Endotoxines", "item": "https://questionsmedicales.fr/mesh/D004731" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Endotoxines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Endotoxines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Endotoxines", "description": "Comment diagnostiquer une intoxication par endotoxines ?\nQuels tests sont utilisés pour détecter les endotoxines ?\nQuels signes cliniques indiquent une exposition aux endotoxines ?\nLes endotoxines peuvent-elles être détectées dans le sang ?\nQuel rôle joue la culture bactérienne dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Prostate&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Endotoxines", "description": "Quels sont les symptômes d'une intoxication par endotoxines ?\nComment les endotoxines affectent-elles le système immunitaire ?\nLes endotoxines causent-elles des douleurs ?\nQuels signes indiquent un choc septique dû aux endotoxines ?\nLes symptômes varient-ils selon l'exposition ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Prostate&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Endotoxines", "description": "Comment prévenir l'exposition aux endotoxines ?\nLes vaccins peuvent-ils prévenir les infections à endotoxines ?\nQuelles mesures de sécurité en laboratoire sont nécessaires ?\nLes antibiotiques préventifs sont-ils efficaces ?\nComment réduire le risque d'infections nosocomiales ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Prostate&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Endotoxines", "description": "Quel est le traitement principal pour une intoxication par endotoxines ?\nLes corticostéroïdes sont-ils efficaces contre les endotoxines ?\nComment traiter le choc septique causé par des endotoxines ?\nLes antidotes existent-ils pour les endotoxines ?\nQuelle est l'importance de la prise en charge précoce ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Prostate&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Endotoxines", "description": "Quelles sont les complications possibles d'une intoxication par endotoxines ?\nComment les endotoxines affectent-elles les organes ?\nLe syndrome de détresse respiratoire est-il lié aux endotoxines ?\nLes endotoxines peuvent-elles causer des dommages neurologiques ?\nQuel est le pronostic après une exposition aux endotoxines ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Prostate&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Endotoxines", "description": "Quels sont les principaux facteurs de risque d'intoxication par endotoxines ?\nLes infections bactériennes augmentent-elles le risque d'endotoxines ?\nLes interventions chirurgicales augmentent-elles le risque ?\nLe diabète est-il un facteur de risque pour les endotoxines ?\nLes conditions de vie insalubres augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Prostate&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication par endotoxines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins, cultures et évaluation clinique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les endotoxines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Le test de limule et les tests ELISA sont couramment utilisés." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une exposition aux endotoxines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons, hypotension et tachycardie sont des signes fréquents." } }, { "@type": "Question", "name": "Les endotoxines peuvent-elles être détectées dans le sang ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests spécifiques peuvent détecter les endotoxines dans le sang." } }, { "@type": "Question", "name": "Quel rôle joue la culture bactérienne dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'identifier la source bactérienne des endotoxines." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une intoxication par endotoxines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, frissons, douleurs abdominales et confusion." } }, { "@type": "Question", "name": "Comment les endotoxines affectent-elles le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles provoquent une réponse inflammatoire excessive, pouvant mener à un choc." } }, { "@type": "Question", "name": "Les endotoxines causent-elles des douleurs ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent provoquer des douleurs abdominales et musculaires." } }, { "@type": "Question", "name": "Quels signes indiquent un choc septique dû aux endotoxines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Hypotension, tachycardie, confusion et peau froide sont des signes clés." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'exposition ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité des symptômes dépend de la dose et de la durée d'exposition." } }, { "@type": "Question", "name": "Comment prévenir l'exposition aux endotoxines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les environnements contaminés et respecter les protocoles d'hygiène." } }, { "@type": "Question", "name": "Les vaccins peuvent-ils prévenir les infections à endotoxines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de vaccin spécifique contre les endotoxines, mais contre certaines bactéries." } }, { "@type": "Question", "name": "Quelles mesures de sécurité en laboratoire sont nécessaires ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection individuelle et des procédures de désinfection." } }, { "@type": "Question", "name": "Les antibiotiques préventifs sont-ils efficaces ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être utilisés dans certains cas à risque, mais pas systématiquement." } }, { "@type": "Question", "name": "Comment réduire le risque d'infections nosocomiales ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Améliorer l'hygiène hospitalière et le contrôle des infections est essentiel." } }, { "@type": "Question", "name": "Quel est le traitement principal pour une intoxication par endotoxines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des antibiotiques et des soins de soutien pour stabiliser le patient." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces contre les endotoxines ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent réduire l'inflammation, mais leur utilisation est controversée." } }, { "@type": "Question", "name": "Comment traiter le choc septique causé par des endotoxines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement nécessite des fluides intraveineux et des vasopresseurs." } }, { "@type": "Question", "name": "Les antidotes existent-ils pour les endotoxines ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique." } }, { "@type": "Question", "name": "Quelle est l'importance de la prise en charge précoce ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une prise en charge rapide améliore les chances de survie et réduit les complications." } }, { "@type": "Question", "name": "Quelles sont les complications possibles d'une intoxication par endotoxines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent le choc septique, l'insuffisance organique et la mort." } }, { "@type": "Question", "name": "Comment les endotoxines affectent-elles les organes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent provoquer une défaillance multi-organique en raison de l'inflammation." } }, { "@type": "Question", "name": "Le syndrome de détresse respiratoire est-il lié aux endotoxines ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inflammation pulmonaire peut entraîner un syndrome de détresse respiratoire." } }, { "@type": "Question", "name": "Les endotoxines peuvent-elles causer des dommages neurologiques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent provoquer des troubles neurologiques en raison de l'inflammation systémique." } }, { "@type": "Question", "name": "Quel est le pronostic après une exposition aux endotoxines ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Le pronostic dépend de la rapidité du traitement et de la gravité de l'exposition." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'intoxication par endotoxines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les patients immunodéprimés, les personnes âgées et les hospitalisés sont à risque." } }, { "@type": "Question", "name": "Les infections bactériennes augmentent-elles le risque d'endotoxines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections par des bactéries Gram-négatives sont un facteur de risque majeur." } }, { "@type": "Question", "name": "Les interventions chirurgicales augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les interventions chirurgicales peuvent exposer à des endotoxines, surtout en cas d'infection." } }, { "@type": "Question", "name": "Le diabète est-il un facteur de risque pour les endotoxines ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut affaiblir le système immunitaire et augmenter le risque d'infections." } }, { "@type": "Question", "name": "Les conditions de vie insalubres augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles favorisent la prolifération bactérienne et l'exposition aux endotoxines." } } ] } ] }

Sources (10000 au total)

Presence of HPV in prostate tissue from patients submitted to prostate biopsy.

Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat... Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus.... Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ... There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....

Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review.

To assess the effects of prostatic arterial embolisation (PAE) compared to other procedures for treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).... We included randomised controlled trials (RCTs), as well as non-randomised studies (NRSs) enrolling men with BPH undergoing PAE vs other surgical interventions via a comprehensive search up until 8 No... We found data to inform two comparisons: PAE vs transurethral resection of prostate (TURP; six RCTs and two NRSs), and PAE vs sham (one RCT). This abstract focuses on the primary outcomes in a compari... Compared to TURP, the impact on urological symptoms and QoL improvement as perceived by patients appears to be similar. This review did reveal major uncertainty as to how major adverse events compare....

Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.

With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di... We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ... An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve... This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...

Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.

To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n... The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit... In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ... A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...

Prostatic artery embolization compared to transurethral resection of the prostate and prostatic urethral lift: a real-world population-based study.

There are growing interests for minimally invasive surgical techniques (MISTs) for the treatment of benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS). Prostatic artery ... We present an observational population-based study of 12,902 men with BPH in New York State who received PAE, TURP, and PUL in outpatient and ambulatory surgery settings from 2014 to 2018. For short-t... Of 12 902 men, 335 had PAE, 11,205 had TURP, and 1362 had PUL. PAE patients had the highest 30-day (19.9%) and 90-day (35.6%) risks of readmission to inpatient or ER (p < 0.01). Non-specific abdominal... In a real-world population, PAE was associated with the most frequent 30-day and 90-day readmission to inpatient or ER and the highest retreatment rate among all surgical techniques even when controll...

Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?

Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga... Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu... Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114... The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...

Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?

The paradigm of focal therapy's role in metastatic patients is being challenged by evolving attitudes and emerging data. At the current time, specifically regarding prostate cancer, does the evidence ... We searched the literature via PubMed, MEDLINE, and Embase for studies from 2014 to the present addressing focal therapy with non-palliative intent in metastatic prostate cancer patients, emphasizing ... Current evidence is strongest, and in our opinion practice-changing, for prostate-directed RT in de novo metastatic patients with low metastatic burden. Metastasis-directed therapy with SBRT is consis...